Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its patented drug candidate Lucid-MS toward phase 2 clinical trials for multiple sclerosis (MS), according to a recent editorial from AINewsWire. Lucid-MS is a first-in-class compound designed to directly protect the myelin sheath damaged by MS, distinguishing it from existing therapies that primarily target the immune system. This nonimmunomodulatory, neuroprotective approach aims to prevent myelin degradation, the underlying cause of disability in MS.
The company has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration and is preparing for a phase 2 clinical trial following the successful completion of phase 1 safety studies and key toxicology programs. More than a decade of preclinical research supports Lucid-MS, including studies demonstrating preservation of myelin integrity, reduced degradation, and improved functional recovery in animal models.
Quantum BioPharma is also collaborating with Massachusetts General Hospital on validation of a novel PET imaging technique designed to directly measure myelin integrity in MS patients. This tool could help evaluate the effectiveness of remyelinating therapies, potentially accelerating the development of new treatments for MS.
The report also noted recent clinical and regulatory developments from Novartis AG (NYSE: NVS), Merck & Co. Inc. (NYSE: MRK), TG Therapeutics Inc. (NASDAQ: TGTX), and Bristol Myers Squibb Company (NYSE: BMY), underscoring continued innovation across autoimmune, immune-mediated, and chronic inflammatory disease treatment markets.
Quantum BioPharma is a biopharmaceutical company focused on building a portfolio of innovative assets for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is dedicated to the research and development of Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. The company also invented UNBUZZD and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake and royalty payments of 7% of sales until $250 million is reached, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products for pharmaceutical and medical uses.
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM. For the full press release, visit https://ibn.fm/6ylQf.
